Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

EGRX PEER ANALYSIS

Eagle Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

EGRXEagle Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - Specialty & Generic

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
EGRXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
EGRX-75.2%TRILC-94.3%HIK-18.5%DEVA+24.8%TLRY-7.0%HLN-3.3%
Year-to-Date (YTD)
EGRX-4.3%TRILC-92.8%HIK+2.5%DEVA+17.5%TLRY-49.8%HLN-3.1%
1-Year
Split-adjusted
EGRX-75.2%BTAI-43.0%
Year-to-Date (YTD)
EGRX-4.3%BTAI-31.3%

Key Metric Comparison

P/E

Lower is better
EGRX0.57TRILC—HIK11.40DEVA—TLRY—HLN30.79Median 21.35

ROE

Higher is better
EGRX6.4%TRILC-6.0%HIK16.4%DEVA-3.6%TLRY-63.6%HLN6.3%Median 6.4%

Net Margin

Higher is better
EGRX6.0%TRILC-2.2%HIK12.0%DEVA-4.4%TLRY-158.8%HLN12.6%Median 4.0%

Revenue Growth

Higher is better
EGRX-5.4%TRILC32.0%HIK7.4%DEVA7.7%TLRY3.8%HLN-26.7%Median 7.5%

P/E

Lower is better
EGRX0.57BTAI—Median 21.35

ROE

Higher is better
EGRX6.4%BTAI—Median 6.4%

Net Margin

Higher is better
EGRX6.0%BTAI-11,078.5%Median 4.0%

Revenue Growth

Higher is better
EGRX-5.4%BTAI-63.3%Median 7.5%

All Metrics

Valuation
MetricEGRXTRILCHIKDEVATLRYHLNInd. Median
P/E0.57●—11.40——30.7921.35
P/B0.03●0.611.770.510.321.941.77
EV/EBITDA1.14●3.518.726.74—18.9012.18
P/S0.03●0.231.370.700.583.872.08
Financial Health
MetricEGRXTRILCHIKDEVATLRYHLNInd. Median
Current Ratio2.160.991.822.002.79●0.922.22
Debt/Equity28.4%207.6%61.8%23.1%20.4%●52.3%46.3%
NetDebt/EBITDA0.992.711.870.89-0.07●3.501.24
Profitability
MetricEGRXTRILCHIKDEVATLRYHLNInd. Median
Net Margin6.0%-2.2%12.0%-4.4%-158.8%12.6%●4.0%
ROE6.4%-6.0%16.4%●-3.6%-63.6%6.3%6.4%
ROA4.0%-1.8%7.5%●-2.5%-49.7%3.2%3.4%
EBITDA Margin22.1%28.5%●20.0%12.0%-156.2%25.2%18.2%
Growth + Dividend
MetricEGRXTRILCHIKDEVATLRYHLNInd. Median
Rev. Growth-5.4%32.0%●7.4%7.7%3.8%-26.7%7.5%
NI Growth-31.7%—12.2%●——-14.2%5.0%
Div. Yield2.8%0.0%5.4%●0.0%—2.0%2.0%
Payout1.6%0.0%45.2%0.0%—40.0%0.8%
Valuation
MetricEGRXBTAIInd. Median
P/E0.57—21.35
P/B0.03-0.13●1.77
EV/EBITDA1.14—12.18
P/S0.03●19.752.08
Financial Health
MetricEGRXBTAIInd. Median
Current Ratio2.16●0.622.22
Debt/Equity28.4%-95.0%●46.3%
NetDebt/EBITDA0.99-1.44●1.24
Profitability
MetricEGRXBTAIInd. Median
Net Margin6.0%●-11,078.5%4.0%
ROE6.4%—6.4%
ROA4.0%●-207.6%3.4%
EBITDA Margin22.1%●-8,509.3%18.2%
Growth + Dividend
MetricEGRXBTAIInd. Median
Rev. Growth-5.4%●-63.3%7.5%
NI Growth-31.7%—5.0%
Div. Yield2.8%—2.0%
Payout1.6%—0.8%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on EGRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jun 26, 26. This content is for informational purposes only and is not investment advice.